Pharmaceutical Sciences. 2025;31(4):440-S1
doi:10.34172/PS.025.42799
https://ps.tbzmed.ac.ir/

Table S1. Composition of different niosomal formulations containing FL (5mg/ml)

Name	Constituents of the lipid phase	Molar ratio*	Concentration (mg/ml)
F 1	Span20/Tween20/Cholesterol	25/25/50	5.19/18.29/11.61
F 2	Span20/Tween20/Cholesterol	35/35/30	7.27/25.75/6.96
F 3	Span20/Tween20/Cholesterol	45/45/10	9.34/33.10/2.32
F 4	Span40/Tween40/Cholesterol	25/25/50	6.05/19.23/11.61
F 5	Span40/Tween40/Cholesterol	35/35/30	8.46/26.92/6.96
F 6	Span40/Tween40/Cholesterol	45/45/10	10.88/34.61/2.32
F 7	Span60/Tween60/Cholesterol	25/25/50	6.47/19.65/11.61
F 8	Span60/Tween60/Cholesterol	35/35/30	9.05/27.51/6.96
F 9	Span60/Tween60/Cholesterol	45/45/10	11.64/35.37/2.32

* The total concentration of the lipid phase in all formulations was 60 μM.

Table S2. Result of FL niosomal gel content uniformity test and pH measurement after preparation and storage at room temperature (Mean ± SD, n=3).

Formulation name	Content uniformity %	pH				
		0	48 h	1 week	1 month	6 months
FNG1	102.1±1.1	6.12±0.15	5.99±0.25	6.13±0.11	5.90±0.14	5.81±0.22
FNG2	98.4±2.1	6.22±0.28	6.11±0.09	5.85±0.14	5.71±0.27	5.24±0.16
FNG3	91.8±1.5	7.71±0.23	7.31±0.31	6.96±0.11	6.88±0.05	6.23±0.07
FNG4	95.5±1.7	7.02±0.12	6.91±0.37	6.58±0.14	6.29±0.25	6.10±0.19
FNG5	99.3±0.9	6.30±0.21	6.19±0.18	6.25±0.36	5.96±0.11	6.10±0.31
FNG6	101.8±1.4	5.80±0.11	5.71±0.29	5.52±0.14	5.81±0.22	5.31±0.18

Table S3. Results of chemical stability study of FNG 1 formulation.

Temperature (ºC)	**Remaining percentages (Mean ± SD , n=3)**			
	1 week	1 month	3 months	6 months
-8	100.10 ± 0.09	100.16 ± 0.14	99.90 ± 0.19	99.20 ± 0.12
4	100.03 ± 0.11	100.08 ± 0.07	99.10 ± 0.20	97.66 ± 0.21
25	100.09 ± 0.05	99.10 ± 0.07	97.20 ± 0.13	94.30 ± 0.30
40	100.01 ± 0.13	94.50 ± 0.21	91.10 ± 0.29	88.54 ± 0.93